ABSTRACT. Polymyxin B given in conjunction with ampicillin protects infant rats against death from overwhelming Haemophilus injluenzae type b infection. This study was undertaken to examine whether polymyxin B would mitigate the effects of brain damage caused by meningitis. Six-to 7-d-old Sprague-Dawley rats were infected subcutaneously into the nape with lo7 cfu Haemophilus influenzae type b strain Eagan. This dose consistently caused bacteremia (1.2 x lo5 cfu/mL) and meningitis (0.5 x lo5 cfu/mL) in pilot studies. Twenty-four h after infection, all animals received intraperitoneal treatment consisting in either ampicillin alone (400 mg/kg x 4 q 3 h) repeated 12 h later, n = 15 or combined with polymyxin B (0.1 mg/kg/ dose) n = 16. At age 2 mo, they were taken off ad libitum feeding and maintained at 80% of their wt. They were then conditioned to receive a food pellet by pressing a lever (continuous reinforcement). The next day, the time lapse between placement and pressing the lever for the first time was recorded (conditioned operant response or latency). Three wk later, the animals were put in the test chamber again and the time to press the lever (latency), as well as the time required to obtain 100 pellets (rate) were recorded. Animals who received polymyxin B had a significantly shorter reaction time; mean 34 s, SEM 2 5.7 versus mean 88 s, SEM f 26.3, P 5 0.05 and performed significantly faster in obtaining 100 pellets; mean 925 s, SEM f 72.1 versus mean 1283 s, SEM + 126.3, p 5 0.02 (analysis of variance, Scheffe test). Adjunctive antiinflammatory therapy with low dose polymyxin B appears to be a promising, inexpensive, and readily available mode of treatment for further study with eventual future application in the treatment of children with H. influenzae type b meningitis. 26: ;496-499, 1989) Approximately 18 000 pediatric cases of invasive infection with Haemophilus injluenzae type b per year are recorded in the United States, and 900 to 1200 of these children die (1-3). Most children with H. injluenzae type b meningitis are under 5 y of age and approximately 75% are less than 18 mo of age. These younger children cannot be protected by currently approved vaccines (3-5). Permanent sequelae from meningitis have been observed in one-third to one-half of survivors in the past (6, 7)
(Pediatr Res